Status:
COMPLETED
Urinary Excretion of Acetylamantadine by Cancer Patients
Lead Sponsor:
University of Manitoba
Collaborating Sponsors:
Canadian Institutes of Health Research (CIHR)
BioMark Technologies Inc.
Conditions:
Cancer
Eligibility:
All Genders
18-85 years
Phase:
PHASE2
Brief Summary
The investigators have determined that the drug amantadine hydrochloride is metabolized by acetylation by a specific enzyme named spermidine/spermine N-acetyltransferase (SSAT). This enzyme is increas...
Detailed Description
When patients present to their physician with symptoms of cancer at a later stage of development, survival tends to be poorer. Earlier diagnosis of cancer is expected to provide improved survival of p...
Eligibility Criteria
Inclusion
- Either a medical diagnosis of cancer, or determination of general good health after a medical check-up within two weeks of participation in the study
Exclusion
- Allergy to amantadine hydrochloride
- Chronic liver or kidney disease
- Chronic disease state not controlled by drug therapy, e.g. hypertension
- Pregnancy
Key Trial Info
Start Date :
December 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2008
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00755898
Start Date
December 1 2003
End Date
July 1 2008
Last Update
November 30 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Manitoba
Winnipeg, Manitoba, Canada, R3E 0W3